Maria Di Bartolomeo

机构：Fondazione IRCCS Istituto Nazionale dei Tumori · ORCID：0000-0002-7954-6609

发表论文 555 篇 · 总被引 16179 次 · h-index 61

代表论文

• Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO (2024 · Annals of Oncology · 被引 91)
• Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 45)
• HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 (2024 · Nature Communications · 被引 29)
• Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial (2024 · The Lancet Oncology · 被引 27)
• Remote Rehabilitation and Virtual Reality Interventions Using Motion Sensors for Chronic Low Back Pain: A Systematic Review of Biomechanical, Pain, Quality of Life, and Adherence Outcomes (2025 · Technologies · 被引 15)
• Effectiveness and Adherence of Pharmacological vs. Non-Pharmacological Technology-Supported Smoking Cessation Interventions: An Umbrella Review (2025 · Healthcare · 被引 7)